279 related articles for article (PubMed ID: 15668455)
1. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
[No Abstract] [Full Text] [Related]
2. Use of apomorphine in clinical practice.
MacMahon DG
Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
[No Abstract] [Full Text] [Related]
3. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Giménez de Béjar V; Carballo-Cordero M
Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
[TBL] [Abstract][Full Text] [Related]
5. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
6. Peripheral edema and dopamine agonists in Parkinson disease.
Tan EK
Arch Neurol; 2007 Oct; 64(10):1546-7; author reply 1547. PubMed ID: 17923645
[No Abstract] [Full Text] [Related]
7. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
9. Panniculitis in association with apomorphine infusion.
Acland KM; Churchyard A; Fletcher CL; Turner K; Lees A; Dowd PM
Br J Dermatol; 1998 Mar; 138(3):480-2. PubMed ID: 9580803
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of later phases of Parkinson disease].
Tison F
Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
[No Abstract] [Full Text] [Related]
11. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
12. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.
van Hilten JJ; Wagemans EA; Ghafoerkhan SF; van Laar T
Clin Neuropharmacol; 1997 Oct; 20(5):402-8. PubMed ID: 9331516
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
Poltawski L; Edwards H; Todd A; Watson T; Lees A; James CA
Mov Disord; 2009 Jan; 24(1):115-8. PubMed ID: 19006068
[TBL] [Abstract][Full Text] [Related]
14. [Current treatment strategies for Parkinson's disease].
Südmeyer M; Wojtecki L; Schnitzler A
Fortschr Neurol Psychiatr; 2011 Dec; 79(12):733-43. PubMed ID: 22161168
[No Abstract] [Full Text] [Related]
15. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
[No Abstract] [Full Text] [Related]
16. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
[TBL] [Abstract][Full Text] [Related]
17. Future delivery systems for apomorphine in patients with Parkinson's disease.
van Laar T; Van der Geest R; Danhof M
Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
[No Abstract] [Full Text] [Related]
18. [Parkinson disease].
Moore AP; Clarke CE
Praxis (Bern 1994); 2001 Jun; 90(23):1041-6. PubMed ID: 11447724
[No Abstract] [Full Text] [Related]
19. [Presentation].
García-Ruiz PJ; Luquin MR; Martínez-Castrillo JC
Rev Neurol; 2012; 55 Suppl 1():S1. PubMed ID: 23169226
[No Abstract] [Full Text] [Related]
20. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Koller W; Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
